NCT00955396

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

A Randomized, Double-blind, Placebo-controlled Cross-over Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

In this study the investigators will determine whether there is any effect of GSK1014802 on ambulatory blood pressure. This will be a randomized, double-blind, placebo-controlled, repeat dose, 2 period cross-over study conducted in healthy male and female subjects. Approximately 60 subjects will be randomised to receive GSK1014802 400 mg bid and placebo for 36 days with at least 1 week between treatment sessions. A follow-up will occur 7-14 days after the last dose.

Detailed description

This study, previously posted by GlaxoSmithKline (GSK), was transitioned to Convergence Pharmaceuticals, Ltd., which spun off from GSK. Convergence Pharmaceuticals, Ltd., has now been acquired by Biogen.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	GSK1014802	Tablets
DRUG	Placebo	Tablets

Timeline

• Start date: 2009-07-31
• Primary completion: 2009-12-31
• Completion: 2009-12-31
• First posted: 2009-08-10
• Last updated: 2017-10-16

Locations

1 site across 1 country: United States